Blog - QualityStocks

FridayAug 28, 2026 9:45 am

Gold’s Resilience Signals a Changing Market as Lahontan Gold Advances Santa Fe Toward Potential 2027 Restart

Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising. Gold has demonstrated remarkable resilience despite periodic pressure from higher bond yields, while central-bank buying, geopolitical uncertainty and concerns surrounding currencies and sovereign debt continue supporting demand for the precious metal. China's move to restrict certain retail paper-gold products could further reshape investor demand, although the long-term impact on physical gold remains uncertain. For Lahontan Gold, a sustained gold market could provide an important backdrop as the company advances its flagship Santa Fe Mine toward a potential return to production in 2027 following a…

FridayAug 28, 2026 9:00 am

SS Innovations International Inc. (NASDAQ: SSII) Indian Surgical Robotics Growth Points to Broader Market Opportunity

SS Innovation’s SSi Mantra system was used in more than 50 robotic surgeries in a single day at Mohak Bariatrics and Robotics in Indore, highlighting growing clinical utilization in India. The milestone comes as SS Innovations reports 224 SSi Mantra systems installed across 12 countries, providing a growing installed base for future procedure and instrument revenue. Second-quarter 2026 installations reached 30 systems, above the 25 systems modeled by the analyst cited in the supplied report. Quarterly revenue reached $13.9 million, up 39% year over year, while system sales increased 41% to $12.4 million. FDA review of the SSi Mantra 510(k)…

ThursdayAug 27, 2026 3:38 pm

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug development increasingly expands beyond controlling inflammation toward neuroprotection and myelin preservation. Preclinical studies demonstrated myelin preservation and functional recovery in animal models, while the company’s Phase 1 program generated safety and pharmacokinetic data supporting further development. The U.S.…

ThursdayAug 27, 2026 3:21 pm

QualityStocksNewsBreaks – Dune Oil Corp. (CSE: DUNE) (OTCQB: TRLEF) (FSE: Z621) Announces Leadership Appointments and Sets 2026 Annual General Meeting

Dune Oil (CSE: DUNE) (OTCQB: TRLEF) (FSE: Z621) announced several leadership appointments, including the appointment of President Scott Lower as CEO and Jordan Coleman as chief operating officer. Sean Stofer, who served as interim CEO during the company transition, will continue as chairman and a director. Dune also appointed Neil Maedel to its board, adding more than 45 years of capital-markets, investment-banking and international resource-sector experience. Dune also announced that its 2026 Annual General Meeting of Shareholders ("AGM") will be held Nov. 16, 2026. Shareholders will be asked to set the number of directors at six, elect directors for the ensuing year, appoint…

ThursdayAug 27, 2026 3:07 pm

QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40 enrolled patients closely match the historical control group in baseline characteristics. In Europe, where GelrinC already has CE Mark approval, Regentis is preparing for broader commercialization through surgeon training, an expanding network of Centers of Excellence…

ThursdayAug 27, 2026 2:29 pm

QualityStocksNewsBreaks – Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position among OTC-listed companies through consistent financial growth, timely reporting, vertical integration, prudent capital allocation, and ownership of hard real estate assets. Revenue increased to $35.7 million in FY2026 from $33.1 million in FY2025 and $11.95 million in FY2024, while gross profit rose to $25.5 million from $24.3 million and $7.8 million. The company attributes this progress to strategic investments and acquisitions made without adding debt, particularly its purchase of Avenvi, a real estate company whose 13-property portfolio includes the Texas property housing ETST’s Mister Meds…

ThursdayAug 27, 2026 1:50 pm

QualityStocksNewsBreaks – AtlasClear Holdings Inc. (NYSE American: ATCH) to Spotlight Tech-Enabled Financial Services Platform in New York

AtlasClear Holdings (NYSE American: ATCH) will participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference in New York City on September 9–10, with President Craig Ridenhour and Executive Chairman John Schaible scheduled to deliver an investor presentation and meet one-on-one with investors. The conference brings together growth companies, investors and industry leaders across life sciences, healthcare and other emerging sectors. AtlasClear is focused on building a technology-enabled financial services platform to provide modern clearing solutions to underserved small and mid-sized financial institutions. To view the full press release, visit https://ibn.fm/XSEus About AtlasClear Holdings Inc. AtlasClear Holdings…

ThursdayAug 27, 2026 1:30 pm

VERAXA Biotech AG (NASDAQ: VRXA), Secarna Partnership Milestone Opens New Potential Market for Conjugation Technology

VERAXA Biotech and Secarna Pharmaceuticals have reported an initial in vitro proof of concept for an antibody oligonucleotide conjugate (“AOC”) developed through their research alliance. The AOC candidate demonstrated greater potency than the equivalent unconjugated oligonucleotide in early testing, providing a first experimental validation of the collaboration. AOCs are an emerging class of antibody-guided therapies designed to use an antibody to deliver therapeutic oligonucleotides selectively to disease-relevant cells. VERAXA contributes antibody conjugation expertise and proprietary click chemistry, allowing it to participate in AOCs without shifting its core oncology strategy. The collaboration adds to VERAXA’s growing partnering track record, which also…

ThursdayAug 27, 2026 12:48 pm

QualityStocksNewsBreaks – AZIO AI Holdings, Inc. (NASDAQ: AZIO) Featured in AINewsWire Editorial on Power Constraints Shaping AI Data Center Growth

AZIO AI Holdings (NASDAQ: AZIO) announced its placement in an AINewsWire editorial examining how power constraints are shaping the expansion of AI data centers. The editorial notes that worldwide spending on AI infrastructure is expected to reach approximately $487 billion in 2026 and exceed $1 trillion by 2029, with significant investment directed toward securing land, power and network connectivity in addition to semiconductors. The editorial highlights AZIO AI Atlas One, the inaugural development stage of its broader Project Atlas initiative. Atlas One combines the company south Texas property holdings, contracted behind-the-meter natural gas power generation, dedicated fiber connections and modular computing infrastructure as AZIO AI works to serve growing AI infrastructure demand. To…

ThursdayAug 27, 2026 12:45 pm

Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC

Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue. Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage. With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair. Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? Researchers are pursuing that question through…

Site Search

Company Search